You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in Athletes

    SBC: BIONIKS            Topic: NIAMS

    DESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Polymer-Based Micro-sensor for Radiation Detection and Measurement

    SBC: SEACOAST SCIENCE, INC.            Topic: NIEHS

    Project Summary This Small Business Technology Transfer Phase I project proposes the development and optimization of a commercially viable novel polymer based radiation dosimeter for wide spread deployment The radiation dosimeter proposed herein is a disruptive technology with a significant market Although many commercial radiation dosimeters measure individual radiation load dose quantificatio ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. An Agent-Based Modeling Platform for Environmental Biotechnology

    SBC: MICROVI BIOTECH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant Hazardous compounds in waters and soils are subject to a complex dynamic web of interactions among physical chemical and biological constituents in the natural environment Computational modeling has been proven indispensable to hazardous substances remediation particularly integrated modeling of pollutant hydrogeological fate and transport For the first t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. ANIMAL TESTING OF A BLOCKING ANTIBODY OF PCRV

    SBC: INTERMUNE PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This grant will determine the efficacy of a humanized monoclonal antibody in treating a lethal Pseudomonas-induced lung injury. We have shown that the airspace instillation of a strain of Pseudomonas aeruginosa that contains the type Il system predictably causes lung necrosis, sepsis and death (J Clin Invest 1999). We have also shown th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel STAT3 Inhibitor Targeting its DNA-Binding Site for Drug Development

    SBC: QRKANSWER LLC            Topic: NCI

    DESCRIPTION provided by applicant Cancer is a major public health problem and a leading cause of mortality claiming more than half million lives every year in the US While major progresses have been made in developing targeted anticancer therapeutics many cancers such as lung cancers have no effective treatments Unfortunately many ideal oncogenic targets including transcription factors for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. ANTI-ANDROGENIC MECHANISM OF A NEW COMPOUND

    SBC: ANDROSCIENCE CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patie ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: ADECTO PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. ANTIIDIOTYPE MAB:AN ANTIANGIOGENIC /ANTIMETASTATIC AGENT

    SBC: PIVOTAL BIOSCIENCES            Topic: N/A

    Angiogenesis (new blood vessel formation) is a critical step for tumor growth and metastasis, and its inhibition is currently the most promising approach for cancer therapy. Contortrostatin (ON) is a protein isolated from southern copperhead snake venom, which has been shown to effectively block angiogenesis, as well as metastasis. The potent inhibitory effect of CN on cancer ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government